Effectiveness and Safety study of Oral Triamcinolone (KenacortÂ®) in Patients with Rheumatoid Arthritis in India

Dr Nilesh Patil0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1Patients willing to participate in the study and sign informed consent form.
•2.Patients with a documented history of RA who are on treatment with at least one DMARD for > 6 months and on a stable dose of DMARD(s) for at least 6 weeks
•3.Patients with evidence of disease flare up or having insufficient response to DMARD(s) defined as:
•a.DAS 28 (ESR) >3.2 (moderate disease activity),
•b.Swollen joint count of 4 or more out of 28,
•c.Tender joint count of 4 or more out of 28

•1.Patients treated with glucocorticoids by any route in the past 6 weeks
•2.Patients on more than 3 DMARDs or an additional concomitant biological DMARD
•3.Patients having other types of inflammatory arthritis (e.g. lupus)
•4.Patients having active infection, including tuberculosis
•5.Patients having uncontrolled diabetes or uncontrolled hypertension
•6.Pregnant or nursing women
•7.Suspected inability or unwillingness to comply with study procedures
•8.Known intolerance to any of the ingredients of the formulation
•9.Patients under treatment with any medication that may affect the treatment efficacy evaluation.
•10.Patients under treatment with any medication whose concomitant use may be susceptible to interactions with triamcinolone or may affect safety
•11.Patient having participated in a clinical trial in the last 30 days
•12.Any other condition as deemed unfit by the investigator for the patientâ??s participation in the study.

发起方

Dr Nilesh Patil